No Data
No Data
IMMUNO-BIOLOGICAL LABORATORIES: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Immuno Biological Labs Sees FY Net Y115.00M
Immuno-Biological Laboratories Co. Ltd. also released the following forecasts: GROUP Year Ending Mar 2025 Revenue Y925.00 mln Operating Profit Y120.
Classicom, Confidence I, etc.
<2351>ASJ upward revision, previous fiscal year operating profit forecast 102 million yen ← 80 billion yen <3286>Trust HD shareholder benefit plan newly established <3625> tech firm earnings forecast revision, current fiscal year sales forecast 5.00 billion yen ← 6.00 billion yen <3917>formulating a medium-term management plan involving iRidge from the fiscal year ending 25/3 to the fiscal year ending 27/3 <4165> Played revised upward, sales forecast for the current fiscal year ending 10.809 billion yen ← 10.666 billion yen <43
IMMUNO-BIOLOGICAL LABORATORIES: Notice regarding revisions to full-year earnings forecasts
Backstage [stocks that moved, stocks that were made]
*Hello's <2742> 4500 +21524/2 earnings forecast revised upward. *Motorbike King <3377> 533-44 The operating profit and loss for the first quarter was in deficit of 613 million yen. *Fujikoshi <6474> 3375-120 1st quarter operating profit decreased 69.8%. *Truss OP <6696> 337 +80 The report “Marubeni Information Systems sells power consumption reduction solutions” was viewed as material. *BIRDMAN <7063> 1198 +54 Kao “SPOT
Institute for Immunobiology --- Significant backlash; joint acquisition of a patent for an antibody drug to diagnose and treat gastrointestinal stromal tumors with Tokushima University
Significant backlash. It has been announced that the University of Tokushima and the University of Tokushima have jointly obtained a patent (within Japan) relating to research and development of antibody pharmaceuticals to diagnose and treat GIST (gastrointestinal stromal tumors), which are a type of “sarcoma” derived from immature mesenchymal cells under the mucous membrane of the digestive tract wall of the stomach and intestines. The name of the invention is “c-Kit-positive tumor-specific antibody fragment”. There is currently no impact on the fiscal year ending 25/3, but it is said that if an event affecting business results occurs, it will be promptly disclosed.
No Data